naproxen has been researched along with raloxifene in 5 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (raloxifene) | Trials (raloxifene) | Recent Studies (post-2010) (raloxifene) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 128 | 0 | 61 |
| Protein | Taxonomy | naproxen (IC50) | raloxifene (IC50) |
|---|---|---|---|
| Phospholipase D2 | Homo sapiens (human) | 6.1333 | |
| Aldehyde oxidase 1 | Mus musculus (house mouse) | 0.5 | |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | 2.08 | |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.178 | |
| Estrogen receptor | Homo sapiens (human) | 0.0416 | |
| Estrogen receptor | Rattus norvegicus (Norway rat) | 0.0032 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.666 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.282 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 1.664 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2 | |
| D(2) dopamine receptor | Homo sapiens (human) | 1.174 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 3.698 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.738 | |
| Substance-K receptor | Homo sapiens (human) | 3.989 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 3.864 | |
| Acetylcholinesterase | Homo sapiens (human) | 0.4 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.282 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.973 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 1.45 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.178 | |
| Adenosine receptor A2a | Homo sapiens (human) | 2.111 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 3.576 | |
| Mu-type opioid receptor | Homo sapiens (human) | 1.176 | |
| D(3) dopamine receptor | Homo sapiens (human) | 1.565 | |
| Delta-type opioid receptor | Homo sapiens (human) | 6.644 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 1.602 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.355 | |
| Aldehyde oxidase 1 | Oryctolagus cuniculus (rabbit) | 0.008 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.869 | |
| Aldehyde oxidase | Homo sapiens (human) | 0.0055 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.0003 | |
| Phospholipase D1 | Homo sapiens (human) | 4.9167 | |
| Aldehyde oxidase 1 | Macaca fascicularis (crab-eating macaque) | 0.5 | |
| Estrogen receptor beta | Rattus norvegicus (Norway rat) | 0.1584 | |
| Estrogen receptor beta | Homo sapiens (human) | 0.3051 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.681 | |
| Aldehyde oxidase 1 | Rattus norvegicus (Norway rat) | 1.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for naproxen and raloxifene
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for naproxen and raloxifene
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |